Strides Pharma Science has approved the sale of a majority stake in its wholly owned subsidiary, Pivot Path, to a consortium led by Ascent Capital along with co-investor Vintage Classic for an aggregate consideration of Rs 100 crore.

The transaction, approved by the company's Board of Directors, also includes a primary investment of INR 50 crore by Ascent Capital into Pivot Path to support the company's next phase of expansion. Following the completion of the deal, Strides will retain a 19.95 percent stake in Pivot Path, while the investor consortium will hold 65.05 percent. The remaining 15 percent will be allocated to an Employee Stock Ownership Plan (ESOP) pool.

Under the terms of the agreement, Strides will receive INR 75 crore at the initial closing of the transaction and the remaining INR 25 crore on the first anniversary of the deal's completion.

In a separate regulatory filing, Strides said the transaction values Pivot Path at INR 230 crore on a post-money basis. The company was incubated within Arco Lab, Strides' Global Capability Centre (GCC), where it built expertise in life sciences consulting, digital transformation, quality and compliance and technology-enabled operational services.

Badree Komandur, Managing Director and Group CEO of Strides Pharma Science, said the strategic investment marks an important milestone in Pivot Path's growth journey. He noted that bringing in an experienced investment partner would provide the capital and expertise needed to scale the business independently while enabling Strides to unlock value and retain a meaningful stake in its future growth.

Raja Kumar, Managing Director and Founder of Ascent Capital, said Pivot Path has developed deep expertise in critical pharmaceutical industry functions within the Strides ecosystem. As an independent company, he added, Pivot Path is well positioned to combine advanced technologies, including Agentic AI, with its team of over 400 domain experts to deliver solutions in compliance, digital transformation and drug safety for global pharmaceutical customers.

The investment is expected to strengthen Pivot Path's capabilities, accelerate technology-led innovation and expand its global footprint in life sciences consulting and pharmaceutical services.